Curaleaf acquires Europe's largest independent cannabis company

On April 7, 2021, Curaleaf Holdings, Inc. ("Curaleaf") announced the successful completion of its previously announced acquisition of EMMAC Life Sciences Limited ("EMMAC") for base consideration of approximately US$50 million in cash and 17.5 million shares of Curaleaf, with additional consideration to be paid based upon the successful achievement of performance milestones. Curaleaf simultaneously established Curaleaf International Holdings Limited ("Curaleaf International") in Guernsey to hold the EMMAC investment and further its European expansion.

Further information can be found on Canada Newswire’s website. 

EMMAC is Europe's largest vertically integrated independent cannabis company, bringing cultivation, EU-GMP processing, distribution, and R&D operations across several key European medical cannabis markets, including the United Kingdom, Germany, Italy, Spain and Portugal. EMMAC also has an operational presence and partnerships in European Union countries that are enacting new medical cannabis access programs. EMMAC's cultivation facility based in Portugal is an industry leader in cannabis flower production cost.

Curaleaf is a leading U.S. provider of consumer products in cannabis. As a vertically integrated, high-growth cannabis operator, the company and its brands, including Curaleaf, Select and Grassroots, provide industry-leading service, product selection and accessibility across the medical and adult-use markets. Curaleaf currently operates in 23 states with 101 dispensaries, 23 cultivation sites and over 30 processing sites, and employs over 3,800 team members across the United States.